TARRYTOWN, N.Y. and WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Achyuta Rajaram, 17, of Exeter, NH, won the top award in the Regeneron Science Talent Search (STS) 2024, America’s oldest and most prestigious science and math competition for high school seniors.
The competition, now in its 83rd year, has consistently identified young innovators who become tomorrow’s STEM leaders. The 2024 finalists demonstrated extensive scientific knowledge through research and interviews while showcasing their commitment to addressing societal issues, passion for discovery, noteworthy leadership and community involvement.
Forty finalists, including Achyuta, were honored this evening during an award ceremony emceed by American Broadcaster Soledad O'Brien. More than $1.8 million was awarded to the finalists, who were selected from among the largest entrant pool since the 1960s through a holistic evaluation process.
“Congratulations to the winners of this year’s Regeneron Science Talent Search,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. “The remarkable intellect and ingenuity of these students serves as an inspiration for us all. Their groundbreaking innovations are vital in uncovering the crucial solutions we need now to address our most intractable challenges.”
The Regeneron Science Talent Search empowers young people who are passionate about innovation and using scientific discovery to contribute to improving our world. By providing a national stage to present new ideas and challenge old ways of thinking, the competition encourages and rewards a culture of idea sharing, critical thinking and continuous improvement. It also serves as a catalyst to discovering sustainable solutions to the world’s most pressing challenges. The judging panel considers how these research endeavors, innovative thinking and leadership qualities demonstrate the students’ potential to become future leaders in critical STEM fields.
“Congratulations to the winners of this year’s Regeneron Science Talent Search and to all the brilliant finalists,” said George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chair, President and Chief Scientific Officer of Regeneron, and a top winner in the 1976 STS. “My own participation in the Science Talent Search during my high school years sparked a lifelong commitment to science and set me on my path of inventing and developing new medicines for previously untreatable diseases. Our finalists are only beginning their journeys, and their extraordinary achievements at such a young age give me hope that they will go on to deliver major innovative breakthroughs that will greatly benefit humanity.”
Other top honors from the competition include:
All other finalists received $25,000. All 40 finalists will join the ranks of other STS alumni, many of whom have gone on to have world-changing careers in STEM fields, and some of whom have earned the most esteemed honors in science and math, including the Nobel Prize, National Medal of Science and MacArthur Foundation Fellowships. In total, Regeneron awarded $3.1 million in prizes through the Regeneron Science Talent Search 2024, including $2,000 to each of the top 300 scholars and their schools.
Learn more about Regeneron Science Talent Search at https://www.societyforscience.org/regeneron-sts/.
For media resources, visit https://www.societyforscience.org/2024-regeneron-science-talent-search-media-kit.
About Society for Science
Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its outreach and equity programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter, Instagram and Snapchat (Society4Science).
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for over 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases and rare diseases.
Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono and matching gift programs. Our most significant philanthropic commitments are in the area of early science education, including the Regeneron Science Talent Search and the Regeneron International Science and Engineering Fair (ISEF).
For more information about Regeneron, please visit www.Regeneron.com or follow Regeneron on LinkedIn.
Media Contacts
Joseph Brown, Regeneron
386-283-1323, This email address is being protected from spambots. You need JavaScript enabled to view it.
Gayle Kansagor, Society for Science
703-489-1131, This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$756.81 |
Daily Volume: | 0 |
Market Cap: | US$82.050B |
November 15, 2024 November 13, 2024 November 06, 2024 October 31, 2024 October 24, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB